33,523 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Acquired by Skandinaviska Enskilda Banken AB publ

Key Points

• Skandinaviska Enskilda Banken AB publ has acquired a new stake in AnaptysBio, Inc., purchasing 33,523 shares valued at approximately $623,000.
• Wall Street analysts are optimistic about AnaptysBio, with several upgrading their ratings and raising price targets, including Guggenheim, which increased its target from $54 to $90.
• AnaptysBio reported earnings of ($1.28) per share, exceeding analysts' expectations, along with revenues of $27.77 million for the quarter, contrasting with a consensus estimate of $15.27 million.

Skandinaviska Enskilda Banken AB publ purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 33,523 shares of the biotechnology company's stock, valued at approximately $623,000. Skandinaviska Enskilda Banken AB publ owned 0.11% of AnaptysBio as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in shares of AnaptysBio during the 4th quarter worth $40,000. Vanguard Group Inc. lifted its position in shares of AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after purchasing an additional 143,584 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of AnaptysBio by 240.6% during the 4th quarter. JPMorgan Chase & Co. now owns 114,939 shares of the biotechnology company's stock worth $1,522,000 after purchasing an additional 81,195 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of AnaptysBio by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company's stock worth $6,444,000 after purchasing an additional 21,196 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of AnaptysBio by 1,585.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 5,360 shares during the last quarter.

Insider Activity

In related news, Director Hollings Renton sold 20,925 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the transaction, the director owned 4,965 shares of the company's stock, valued at approximately $117,025.05. This represents a 80.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 33.50% of the company's stock.

AnaptysBio Price Performance

Shares of NASDAQ ANAB traded up $0.14 on Friday, hitting $24.69. The company's stock had a trading volume of 326,863 shares, compared to its average volume of 506,266. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31. The company has a market capitalization of $725.39 million, a price-to-earnings ratio of -5.09 and a beta of -0.20. The stock has a 50 day moving average of $24.00 and a 200-day moving average of $20.15.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.30) by $0.02. The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 125.70% and a negative return on equity of 282.47%. Sell-side analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $22.00 to $38.00 in a research report on Wednesday, June 4th. Guggenheim reissued a "buy" rating and issued a $90.00 price target (up from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. Wedbush reissued an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a research report on Thursday, May 29th. Finally, JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $47.13.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.